Subscribe To

Price Alert Latest News Economic Calendar News

BIXT / Bioxytran's positive Phase 2 trial results featured in ‘Vaccines' peer-reviewed journal

Bioxytran said positive top-line safety and efficacy results from the company's randomized, placebo-controlled Phase 2 clinical trial of its drug candidate Prolectin-M in 34 patients with mild-to-moderate COVID-19 have been featured in the peer-reviewed journal “Vaccines.” The company said in a statement that during the trial, an orally administered Galectin Antagonist in the form of a chewable tablet was administered for seven days. Read More

Demo Live Account See Partner Details

Content Topics

Bioxytran

Positive

Phase

Trial

Results

Featured

Bioxytran s

vaccines

Peer reviewed

Journal

Stock

BIXT

Posted: Mar 29 2023, 16:04

Author Name: Proactive Investors

BIXT News

By Proactive Investors
March 29, 2023

Bioxytran's positive Phase 2 trial results featured in ‘Vaccines' peer-reviewed journal

Bioxytran said positive top-line safety and efficacy results from the company's randomized, placebo-controlled Phase 2 clinical trial of its drug can

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.